减肥药巨头，全球裁员9000人

Core Viewpoint - Novo Nordisk is undergoing a major internal restructuring, including the layoff of 9,000 employees, to save 8 billion Danish kroner (approximately $1.26 billion) annually, amid increasing competition from Eli Lilly in the diabetes and obesity treatment market [1][3]. Group 1: Restructuring and Cost-Saving Measures - The company announced a comprehensive reform to simplify its organizational structure, accelerate decision-making, and reallocate resources to growth opportunities in diabetes and obesity [1]. - A global hiring freeze was implemented earlier, retaining only essential positions [2]. - The layoffs will affect approximately 5,000 positions in Denmark, with a total of 78,400 jobs worldwide [3]. Group 2: Market Challenges and Performance - Novo Nordisk's market share for its weight loss drug Wegovy is declining, leading to a slowdown in sales growth, particularly in the U.S. market [3]. - The company's market capitalization has dropped significantly, from a peak of $650 billion to $185 billion this year [3][4]. - The company has issued profit warnings, citing increased competition from generic drug manufacturers allowed to produce similar formulations of Wegovy [3].